Norges Bank
SPRY icon

Norges Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Norges Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-243,100
Closed -$1.63M – 2026
2023
Q2 		$1.63M Buy
243,100
+89,568
+58% +$598K ﹤0.01% 1887
2023
Q1 		$999K Buy
+153,532
New +$1.18M ﹤0.01% 2002
2021
Q1 		– Sell
-5,000
Closed -$232K – 2193
2020
Q4 		$232K Buy
+5,000
New +$167K ﹤0.01% 2101

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Norges Bank's SPRY Position: Q3 2023 in Review

Norges Bank sold out of ARS Pharmaceuticals (SPRY) in Q3 2023, closing a stake of 243,100 shares — an estimated $1.63M sold.

Norges Bank first reported a position in SPRY in Q4 2020 and held it in 3 quarters. The position peaked at $1.63M in Q2 2023. 97 funds tracked by Wall St. Rank hold SPRY as of Q3 2023.

  • Norges Bank reported no remaining ARS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Norges Bank sold 243,100 ARS Pharmaceuticals shares in Q3 2023, an estimated $1.63M.
  • Norges Bank first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Norges Bank's ARS Pharmaceuticals position peaked at $1.63M in Q2 2023.
  • 97 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.